Market openADR
Evotec/$EVO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Ticker
$EVO
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,007
Website
Evotec Metrics
BasicAdvanced
$1.5B
-
-$1.02
0.98
-
Price and volume
Market cap
$1.5B
Beta
0.98
52-week high
$7.98
52-week low
$2.85
Average daily volume
159K
Financial strength
Current ratio
2.093
Quick ratio
1.592
Long term debt to equity
43.007
Total debt to equity
48.535
Interest coverage (TTM)
-5.75%
Management effectiveness
Return on assets (TTM)
-1.77%
Return on equity (TTM)
-16.25%
Valuation
Price to revenue (TTM)
0.934
Price to book
1.5
Price to tangible book (TTM)
2.15
Price to free cash flow (TTM)
-3.467
Growth
Revenue change (TTM)
-5.33%
Earnings per share change (TTM)
80.05%
3-year revenue growth (CAGR)
10.79%
3-year earnings per share growth (CAGR)
-13.53%
What the Analysts think about Evotec
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Evotec Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Evotec Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Evotec News
AllArticlesVideos
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
Accesswire·5 days ago
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Accesswire·2 months ago
Evotec Announces Change in Management Board
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.5B as of January 27, 2025.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of January 27, 2025.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of January 27, 2025.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.